Uterine leiomyosarcoma: A case report

Kaur, Khushpreet; Kaur, Parneet; Kaur, Arvinder; Singla, Atish

doi:10.4103/0976-7800.145175

Cited by 23 publications

(32 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LMS is considered and is known as an aggressive tumor with high mortality and morbidity (1,5). There is no reliable diagnostic method to distinguish between uterine LMS and benign uterine tumors before surgery.…”

Section: Discussionmentioning

confidence: 99%

“…Hematogenous spread is the most common form, and lymphatic spread is the rare one. Sarcoma is known as an aggressive tumor, meaning that there is still a high risk of local and distant recurrence after the tumor removal (5). LMS in stages I and II, according to the International Federation of Gynecology and Obstetrics (FIGO) staging systems, has a very high risk of relapse, while its survival rate is also poor after relapse.…”

Section: Discussionmentioning

confidence: 99%

“…The war taking five years increases the child deaths under age of 5 by 13%. Also 47% of all the refugees in the world and 50% of asylum seekers and displaced people are women and girls and 44% refugees and asylum seekers are children under the age of 18 (5). As the result of wars and armed conflicts, women are…”

Section: Mortalities and Morbiditiesmentioning

confidence: 99%

See 2 more Smart Citations

Uterine Leiomyosarcoma: A Case Report

Forghani¹,

Kashi²,

Sadegi³

et al. 2017

International Journal of Women’s Health and Reproduction Scienc

View full text Add to dashboard Cite

Introduction: Uterine leiomyosarcoma (LMS) is a rare cancer originated from smooth muscle lining the walls of the uterus. LMS is known as an aggressive tumor with high mortality and morbidity rates as compared to other uterine cancers, despite the disease stage at the time of diagnosis. In most cases, LMS has been misdiagnosed as a benign uterine leiomyoma following hysterectomy or myomectomy. Case Presentation: We presented a 53-year-old G7 L7 woman who had referred to GYN clinic in Amir-al-Momenin hospital for abnormal uterine bleeding (AUB) for 6 months. On physical examination, we found an abdominal mass that had grown rapidly in the last 4 months. The computed tomography (CT) scan results showed a heterogeneous mass extending from the epigastric region to the pelvic area. Following an exploratory laparotomy, histopathology report confirmed the diagnosis of LMS. Her uterus, Fallopian tubes and ovaries were removed during a surgery, and she was referred to a gynecologic oncologist for possible chemotherapy. Conclusion: We found that the surgery is the only treatment for LMS; however, there is a little possibility to diagnose LMS before surgery in the patient with uncertain diagnosis and suspicious of LMS. Analysis of LDH and LDH3 levels along with dynamic diethylenetriaminepentaacetic acid (Gd-DTPA) enhanced, and MRI are recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Uterine Leiomyosarcoma: A Case Report

Forghani¹,

Kashi²,

Sadegi³

et al. 2017

International Journal of Women’s Health and Reproduction Scienc

View full text Add to dashboard Cite

show abstract

“…The discovery stage of the tumor was identified as alone as an independent prognostic factor for overall survival [5]. Thus, the rate of five-year survival is 50% to 55% for stage I and 8% to 12% for stage II, III and IV [14]. Six months after surgery, the patient had no clinical signs and resumed his daily activities.…”

Section: Discussionmentioning

confidence: 99%

Uterine Inversion: An Uncommon Progressive Forme of Leiomyosarcoma Uterine: Case Report and Review of Literature

Horo¹,

Aka²,

Fomba³

et al. 2016

OJOG

View full text Add to dashboard Cite

show abstract

“…LMS is a rare malignancy of uterus that arises from the smooth muscle of uterine wall [18]. Women patients with LMS mostly have no symptoms or a rapidly enlarging pelvic mass [19].…”

Section: Resultsmentioning

confidence: 99%

Can aquaporins be used as diagnostic and prognostic markers for uterine smooth muscle tumours?

Alabalık

Türkçü

Keleş

et al. 2016

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

Generally, uterine leiomyosarcoma is easily diagnosed. However, uterine smooth muscle tumours which show atypical histological features and unusual growth patterns may mimic malignancy and may not be easily diagnosed. In this study, our aim is to show the expressions of Aquaporin3, Aquaporin7 and Aquaporin9 in uterine smooth muscle tumours, and to investigate if aquaglyceroporins can be used as diagnostic and prognostic markers to start rapidly an appropriate treatment for patients with these tumours in order to extend the survival time. We determined that there had been 74 patients diagnosed with uterine smooth muscle tumours. We divided patients into four groups based on the diagnosis: bizarre leiomyoma, smooth muscle tumour of uncertain malignant potential, leiomyosarcoma and leiomyoma. Aquaporin3, Aquaporin7 and Aquaporin9 were detected by using monoclonal anti-Aquaporin3, antiAquaporin7 and anti-Aquaporin9 antibodies, respectively. In leiomyosarcoma group, we observed a statistically significant relation of Aquaporin3 expression with survival time, grade, stage, mitotic index and Ki-67 score. A significant relation of both Aquaporin7 and Aquaporin9 expressions with survival time, grade, stage was not statistically detected in leiomyosarcoma group. The decrease of Aquaporin3 expression can be used as important diagnostic and prognostic marker. Aquaporin7 and Aquaporin9 expressions cannot be used as diagnostic and prognostic markers.

show abstract

Uterine leiomyosarcoma: A case report

Cited by 23 publications

References 8 publications

Uterine Leiomyosarcoma: A Case Report

Uterine Leiomyosarcoma: A Case Report

Uterine Inversion: An Uncommon Progressive Forme of Leiomyosarcoma Uterine: Case Report and Review of Literature

Can aquaporins be used as diagnostic and prognostic markers for uterine smooth muscle tumours?

Contact Info

Product

Resources

About